Targeting central pathway of Glucose‐Dependent Insulinotropic Polypeptide, Glucagon and Glucagon‐like Peptide‐1 for metabolic regulation in obesity and type 2 diabetes

Abstract Obesity and type 2 diabetes are significant public health challenges that greatly impact global well‐being. The development of effective therapeutic strategies has become more and more concentrated on the central nervous system and metabolic regulation. The primary pharmaceutical interventions for the treatment of obesity and uncontrolled hyperglycemia are now generally considered to be incretin‐based anti‐diabetic treatments, particularly glucagon‐like peptide‐1 and glucose‐dependent insulinotropic polypeptide receptor agonists. This is a result of their substantial influence on the central nervous system and the consequent effects on energy balance and glucose regulation. It is increasingly crucial to understand the neural pathways of these pharmaceuticals. The purpose of this review is to compile and present the most recent central pathways regarding glucagon‐like peptide‐1, glucose‐dependent insulinotropic polypeptide and glucagon receptors, with a particular emphasis on central metabolic regulation.